<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Antitrypanosomal activity was performed using trypomastigotes of 
 <italic class="italic">T. brucei</italic>, cultured in Hirumi-9 medium supplemented with 10% inactivated fetal calf serum (FCSi) at 37 °C and 5% CO
 <sub class="sub">2</sub> [
 <xref rid="B45-molecules-24-01615" ref-type="bibr" class="xref">45</xref>]. Assays were performed by adding 1.5 × 10
 <sup class="sup">4</sup> trypomastigotes/well to the EO at the mentioned concentrations. After 72 h of incubation at the same conditions, parasite growth was assessed fluorimetrically by adding resazurin for 24 h at 37 °C. In parallel, activity on amastigotes of 
 <italic class="italic">T. cruzi</italic> was also evaluated. In this case, the EO at tested concentrations was added to 4 × 10
 <sup class="sup">4</sup> amastigotes in 4 × 10
 <sup class="sup">3</sup> MRC-5 cells maintained in minimal essential medium (MEM; Life Technologies, USA) supplemented with 20 mM L-glutamine, 16.5 mM sodium bicarbonate and 5% of FCSi. After an additional incubation for seven days at the previous conditions, parasite growth was assessed by adding the β-galactosidase substrate chlorophenol red β-D-galactopyranoside (Sigma Aldrich, St. Louis, MO, USA) and then incubating for 4 h at 37 °C. The absorbance was then read at 540 nm [
 <xref rid="B46-molecules-24-01615" ref-type="bibr" class="xref">46</xref>]. As reference drugs, suramine for 
 <italic class="italic">T. brucei</italic> and benznidazol for 
 <italic class="italic">T. cruzi</italic> were used, which were kindly donated by WHO-TDR.
</p>
